当前位置: 首页 >> 检索结果
421. Effectiveness of Pelvic Physiotherapy in Children With Functional Constipation Compared With Standard Medical Care.
作者: Marieke L van Engelenburg-van Lonkhuyzen.;Esther M J Bols.;Marc A Benninga.;Wim A Verwijs.;Rob A de Bie.
来源: Gastroenterology. 2017年152卷1期82-91页
Functional constipation (FC) is a common childhood problem often related to pelvic floor muscle dysfunction. We compared the effectiveness of pelvic physiotherapy (PPT) vs standard medical care (SMC) in children with FC.
422. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
作者: Francis K L Chan.;Moe Kyaw.;Tetsuya Tanigawa.;Kazuhide Higuchi.;Kazuma Fujimoto.;Pui Kuan Cheong.;Vivian Lee.;Yoshikazu Kinoshita.;Yuji Naito.;Toshio Watanabe.;Jessica Y L Ching.;Kelvin Lam.;Angeline Lo.;Heyson Chan.;Rashid Lui.;Raymond S Y Tang.;Yasuhisa Sakata.;Yee Kit Tse.;Toshihisa Takeuchi.;Osamu Handa.;Hiroko Nebiki.;Justin C Y Wu.;Takashi Abe.;Tsuyoshi Mishiro.;Siew C Ng.;Tetsuo Arakawa.
来源: Gastroenterology. 2017年152卷1期105-110.e1页
It is not clear whether H2-receptor antagonists (H2RAs) reduce the risk of gastrointestinal (GI) bleeding in aspirin users at high risk. We performed a double-blind randomized trial to compare the effects of a proton pump inhibitor (PPI) vs a H2RA antagonist in preventing recurrent upper GI bleeding and ulcers in high-risk aspirin users.
423. Effect of mobile phone reminder messages on adherence of stent removal or exchange in patients with benign pancreaticobiliary diseases: a prospectively randomized, controlled study.
作者: Yong Gu.;Limei Wang.;Lina Zhao.;Zhiguo Liu.;Hui Luo.;Qin Tao.;Rongchun Zhang.;Shuixiang He.;Xiangping Wang.;Rui Huang.;Linhui Zhang.;Yanglin Pan.;Xuegang Guo.
来源: BMC Gastroenterol. 2016年16卷1期105页
Plastic and covered metal stents need to be removed or exchanged within appropriate time in case of undesirable complications. However, it is not uncommon that patients do not follow the recommendation for further stent management after Endoscopic Retrograde Cholangiopancreatography (ERCP). The effect of short message service (SMS) intervention monthly on the stent removal/exchange adherence in patients after ERCP is unknown at this time.
424. Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck.
作者: Chikatoshi Katada.;Tetsuji Yokoyama.;Tomonori Yano.;Kazuhiro Kaneko.;Ichiro Oda.;Yuichi Shimizu.;Hisashi Doyama.;Tomoyuki Koike.;Kohei Takizawa.;Motohiro Hirao.;Hiroyuki Okada.;Takako Yoshii.;Kazuo Konishi.;Takenori Yamanouchi.;Takashi Tsuda.;Tai Omori.;Nozomu Kobayashi.;Tadakazu Shimoda.;Atsushi Ochiai.;Yusuke Amanuma.;Shinya Ohashi.;Tomonari Matsuda.;Hideki Ishikawa.;Akira Yokoyama.;Manabu Muto.
来源: Gastroenterology. 2016年151卷5期860-869.e7页
Some patients develop multiple squamous cell carcinomas (SCCs) in the upper aerodigestive tract, attributed to field cancerization; alcohol consumption has been associated with this process. We examined the association between multiple areas of dysplastic squamous epithelium with the development of SCC of the esophagus or head and neck cancer, as well as alcohol consumption and smoking.
425. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
作者: Eric Lawitz.;Nancy Reau.;Federico Hinestrosa.;Mordechai Rabinovitz.;Eugene Schiff.;Aasim Sheikh.;Ziad Younes.;Robert Herring.;K Rajender Reddy.;Tram Tran.;Michael Bennett.;Ronald Nahass.;Jenny C Yang.;Sophia Lu.;Hadas Dvory-Sobol.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Brian Pearlman.;Mitchell Shiffman.;Trevor Hawkins.;Michael Curry.;Ira Jacobson.
来源: Gastroenterology. 2016年151卷5期893-901.e1页
The best regimen to re-treat patients who do not respond to direct-acting antivirals (DAAs) and the feasibility of further shortening regimens is unclear. We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection.
426. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
作者: Edward J Gane.;Kris V Kowdley.;David Pound.;Catherine A M Stedman.;Mitchell Davis.;Kyle Etzkorn.;Stuart C Gordon.;David Bernstein.;Gregory Everson.;Maribel Rodriguez-Torres.;Naoky Tsai.;Omer Khalid.;Jenny C Yang.;Sophia Lu.;Hadas Dvory-Sobol.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Myron Tong.;Raymond T Chung.;Kimberly Beavers.;John E Poulos.;Paul Y Kwo.;Mindie H Nguyen.
来源: Gastroenterology. 2016年151卷5期902-909页
Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients.
427. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
作者: Carol A Burke.;Evelien Dekker.;N Jewel Samadder.;Elena Stoffel.;Alfred Cohen.
来源: BMC Gastroenterol. 2016年16卷1期87页
Molecular studies suggest inhibition of colorectal mucosal polyamines (PAs) may be a promising approach to prevent colorectal cancer (CRC). Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. In a clinical trial, this combination (compared with placebo) reduced the 3-year incidence of subsequent high-risk adenomas by >90 %. Familial Adenomatous Polyposis (FAP) is characterized by marked up-regulation of ODC in normal intestinal epithelial and adenoma tissue, and therefore PA reduction might be a potential strategy to control progression of FAP-related intestinal polyposis. CPP FAP-310, a randomized, double-blind, Phase III trial was designed to examine the safety and efficacy of sulindac and DFMO (alone or in combination) for preventing a clinically relevant FAP-related progression event in individuals with FAP.
428. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
作者: Ju Yup Lee.;Nayoung Kim.;Kyung Sik Park.;Hyun Jin Kim.;Seon Mee Park.;Gwang Ho Baik.;Ki-Nam Shim.;Jung Hwan Oh.;Suck Chei Choi.;Sung Eun Kim.;Won Hee Kim.;Seon-Young Park.;Gwang Ha Kim.;Bong Eun Lee.;Yunju Jo.;Su Jin Hong.
来源: BMC Gastroenterol. 2016年16卷1期79页
The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy.
429. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
作者: Edward Gane.;Fred Poordad.;Stanley Wang.;Armen Asatryan.;Paul Y Kwo.;Jacob Lalezari.;David L Wyles.;Tarek Hassanein.;Humberto Aguilar.;Benedict Maliakkal.;Ran Liu.;Chih-Wei Lin.;Teresa I Ng.;Jens Kort.;Federico J Mensa.
来源: Gastroenterology. 2016年151卷4期651-659.e1页
The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (SVR12) in noncirrhotic patients infected with hepatitis C virus (HCV) genotypes (GTs) 1-6. We describe 2 open-label phase 2 studies investigating the efficacy and safety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in GT1- or GT3-infected patients with compensated cirrhosis.
430. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
作者: Vinod S Hegade.;Stuart F W Kendrick.;Robert L Dobbins.;Sam R Miller.;Duncan Richards.;James Storey.;George Dukes.;Kim Gilchrist.;Susan Vallow.;Graeme J Alexander.;Margaret Corrigan.;Gideon M Hirschfield.;David E J Jones.
来源: BMC Gastroenterol. 2016年16卷1期71页
Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels in the systemic circulation and improve pruritus.
431. A randomized controlled trial of an educational video to improve quality of bowel preparation for colonoscopy.
作者: Jin-Seok Park.;Min Su Kim.;HyungKil Kim.;Shin Il Kim.;Chun Ho Shin.;Hyun Jung Lee.;Won Seop Lee.;Soyoung Moon.
来源: BMC Gastroenterol. 2016年16卷1期64页
High-quality bowel preparation is necessary for colonoscopy. A few studies have been conducted to investigate improvement in bowel preparation quality through patient education. However, the effect of patient education on bowel preparation has not been well studied.
432. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
作者: Christoph Sarrazin.;Hadas Dvory-Sobol.;Evguenia S Svarovskaia.;Brian P Doehle.;Phillip S Pang.;Shu-Min Chuang.;Julie Ma.;Xiao Ding.;Nezam H Afdhal.;Kris V Kowdley.;Edward J Gane.;Eric Lawitz.;Diana M Brainard.;John G McHutchison.;Michael D Miller.;Hongmei Mo.
来源: Gastroenterology. 2016年151卷3期501-512.e1页
We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.
433. Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.
作者: Thiago Gagliano-Jucá.;Ronilson A Moreno.;Tiago Zaminelli.;Mauro Napolitano.;Antônio Frederico N Magalhães.;Aloísio Carvalhaes.;Miriam S Trevisan.;John L Wallace.;Gilberto De Nucci.
来源: BMC Gastroenterol. 2016年16卷1期58页
Rebamipide is a gastroprotective agent with promising results against gastric damage induced by non-steroidal anti-inflammatory drugs. The present study evaluated if rebamipide protects against naproxen-induced gastric damage in healthy volunteers. Changes in gastric PGE2 tissue concentration were also evaluated.
434. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
作者: Edward J Gane.;Christian Schwabe.;Robert H Hyland.;Yin Yang.;Evguenia Svarovskaia.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Catherine A Stedman.
来源: Gastroenterology. 2016年151卷3期448-456.e1页
We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.
435. Endoscopic mucosal resection (EMR) versus endoscopic submucosal dissection (ESD) for resection of large distal non-pedunculated colorectal adenomas (MATILDA-trial): rationale and design of a multicenter randomized clinical trial.
作者: Y Backes.;L M G Moons.;J D van Bergeijk.;L Berk.;F Ter Borg.;P C J Ter Borg.;S G Elias.;J M J Geesing.;J N Groen.;M Hadithi.;J C H Hardwick.;M Kerkhof.;M J J Mangen.;J W A Straathof.;R Schröder.;M P Schwartz.;B W M Spanier.;W H de Vos Tot Nederveen Cappel.;F H J Wolfhagen.;A D Koch.
来源: BMC Gastroenterol. 2016年16卷1期56页
Endoscopic mucosal resection (EMR) is currently the most used technique for resection of large distal colorectal polyps. However, in large lesions EMR can often only be performed in a piecemeal fashion resulting in relatively low radical (R0)-resection rates and high recurrence rates. Endoscopic submucosal dissection (ESD) is a newer procedure that is more difficult resulting in a longer procedural time, but is promising due to the high en-bloc resection rates and the very low recurrence rates. We aim to evaluate the (cost-)effectiveness of ESD against EMR on both short (i.e. 6 months) and long-term (i.e. 36 months). We hypothesize that in the short-run ESD is more time consuming resulting in higher healthcare costs, but is (cost-) effective on the long-term due to lower patients burden, a higher number of R0-resections and lower recurrence rates with less need for repeated procedures.
436. Determination of the appropriate propofol infusion rate for outpatient upper gastrointestinal endoscopy-a randomized prospective study.
Pain and discomfort related to endoscopy sessions can be alleviated by sedation, which minimizes anxiety and allows safe examination. For outpatient endoscopy, reliable short-term sedation without secondary effects is required. This study aimed to assess the effects of intravenous propofol rates on sedation in outpatients undergoing upper gastrointestinal endoscopy.
437. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
作者: Ekkehard Bayerdörffer.;Marc-Andre Bigard.;Werner Weiss.;Fermín Mearin.;Luis Rodrigo.;Juan Enrique Dominguez Muñoz.;Hennie Grundling.;Tore Persson.;Lars-Erik Svedberg.;Nanna Keeling.;Stefan Eklund.
来源: BMC Gastroenterol. 2016年16卷48页
Most patients with gastroesophageal reflux disease experience symptomatic relapse after stopping acid-suppressive medication. The aim of this study was to compare willingness to continue treatment with esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with non-erosive reflux disease (NERD) after 6 months.
438. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
作者: Anthony Lembo.;Michael Camilleri.;Richard McCallum.;Ramon Sastre.;Cristian Breton.;Sharon Spence.;Jeffery White.;Michelle Currie.;Keith Gottesdiener.;Elizabeth Stoner.; .
来源: Gastroenterology. 2016年151卷1期87-96.e6页
Gastroparesis is an important complication of diabetes. We investigated the effects of relamorelin (a pentapeptide-selective agonist of the ghrelin receptor that speeds gastric emptying in patients with diabetes) in patients with diabetic gastroparesis.
439. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
作者: Paul J Pockros.;K Rajender Reddy.;Parvez S Mantry.;Eric Cohen.;Michael Bennett.;Mark S Sulkowski.;David E Bernstein.;Daniel E Cohen.;Nancy S Shulman.;Deli Wang.;Amit Khatri.;Manal Abunimeh.;Thomas Podsadecki.;Eric Lawitz.
来源: Gastroenterology. 2016年150卷7期1590-1598页
Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD).
440. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
作者: Miguel Regueiro.;Brian G Feagan.;Bin Zou.;Jewel Johanns.;Marion A Blank.;Marc Chevrier.;Scott Plevy.;John Popp.;Freddy J Cornillie.;Milan Lukas.;Silvio Danese.;Paolo Gionchetti.;Stephen B Hanauer.;Walter Reinisch.;William J Sandborn.;Dario Sorrentino.;Paul Rutgeerts.; .
来源: Gastroenterology. 2016年150卷7期1568-1578页
Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence.
|